HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Rapid onset of efficacy of rasagiline in early Parkinson's disease.

Abstract
Rasagiline is a monoamine oxidase type-B inhibitor used as monotherapy or in addition to levodopa in the treatment of Parkinson's disease (PD). This naturalistic single-blind study was aimed at evaluating the rapidity of onset effect of rasagiline on motor symptoms in a cohort of early relatively elderly PD patients. 102 outpatients (55 males, median age 71 years) have been selected: 26 were PD therapy-naive and 76 received rasagiline as add-on therapy. The third section of the Unified Parkinson's Disease Rating Scale (UPDRSIII) and the Hoehn-Yahr (HY) scale were assessed at baseline and after 1 and 4 weeks thereafter. The mean UPDRS III total score (-6.7 at week 1 and -8.9 at week 4) and single items, as well as mean HY score (-0.40 at week 1 and -0.67 at week 4), significantly decreased from baseline (p < 0.001). Improvements were significant in both therapy-naive and add-on therapy patients: the mean decreases from baseline to week 4 in UPDRSIII and HY score were -8.8 and -0.46, and -9.0 and -0.74, respectively, in the two subgroups. The mean decrease from baseline in UPDRSIII and HY score did not significantly differ in patients aged > or ≤71 years. Rasagiline had a rapid therapeutic effect from the first week of therapy, which further improved at 4 weeks. The rapid onset of action and the absence of a dose titration are important issues in the management of the PD patient.
AuthorsSandro Zambito Marsala, Roberta Vitaliani, Daniele Volpe, Francesca Capozzoli, Luciana Baroni, Enrico Belgrado, Carlo Borsato, Manuela Gioulis, Corrado Marchini, Angelo Antonini
JournalNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (Neurol Sci) Vol. 34 Issue 11 Pg. 2007-13 (Nov 2013) ISSN: 1590-3478 [Electronic] Italy
PMID23636872 (Publication Type: Journal Article, Observational Study)
Chemical References
  • Antiparkinson Agents
  • Indans
  • Monoamine Oxidase Inhibitors
  • rasagiline
Topics
  • Aged
  • Antiparkinson Agents (therapeutic use)
  • Female
  • Humans
  • Indans (therapeutic use)
  • Male
  • Monoamine Oxidase Inhibitors (therapeutic use)
  • Parkinson Disease (drug therapy, physiopathology)
  • Single-Blind Method
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: